As part of efforts by the White House to curb prescription drug spending in the United States, the Food and Drug Administration (FDA) recently unveiled a new plan to support groundbreaking drugs known as biosimilars. Researchers across the country continue making exciting breakthroughs in the development of these innovative therapies, which treat many patients suffering from cancer, rheumatoid arthritis and other chronic diseases.
While other elements of the administration's drug spending plan may have received more immediate attention, the FDA's new Biosimilar Action Plan has the potential for long-term transformation of the nation's healthcare system by spurring competition and making treatments more accessible for millions of American patients.
